WO1995022991A3 - Block copolymers - Google Patents
Block copolymers Download PDFInfo
- Publication number
- WO1995022991A3 WO1995022991A3 PCT/GB1995/000418 GB9500418W WO9522991A3 WO 1995022991 A3 WO1995022991 A3 WO 1995022991A3 GB 9500418 W GB9500418 W GB 9500418W WO 9522991 A3 WO9522991 A3 WO 9522991A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- block copolymers
- units
- prodrugs
- prodrug
- moiety
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7522220A JPH09509443A (en) | 1994-02-28 | 1995-02-28 | Block copolymer |
MX9603680A MX9603680A (en) | 1994-02-28 | 1995-02-28 | Block copolymers. |
EP95909864A EP0748226A1 (en) | 1994-02-28 | 1995-02-28 | Block copolymers |
AU18170/95A AU1817095A (en) | 1994-02-28 | 1995-02-28 | Block copolymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/203,106 | 1994-02-28 | ||
US08/203,106 US5618528A (en) | 1994-02-28 | 1994-02-28 | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995022991A2 WO1995022991A2 (en) | 1995-08-31 |
WO1995022991A3 true WO1995022991A3 (en) | 1995-10-12 |
Family
ID=22752532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/000418 WO1995022991A2 (en) | 1994-02-28 | 1995-02-28 | Block copolymers |
Country Status (8)
Country | Link |
---|---|
US (2) | US5618528A (en) |
EP (1) | EP0748226A1 (en) |
JP (1) | JPH09509443A (en) |
CN (1) | CN1146726A (en) |
AU (1) | AU1817095A (en) |
CA (1) | CA2183766A1 (en) |
MX (1) | MX9603680A (en) |
WO (1) | WO1995022991A2 (en) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100361933B1 (en) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | Chemically defined nonpolymeric bonds form the platform molecule and its conjugate |
PT648503E (en) * | 1993-09-22 | 2000-11-30 | Hoechst Ag | PRO-PROFARMACOS, ITS PRODUCTION AND UTILIZATION |
US6770261B2 (en) * | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US20020064546A1 (en) * | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US6299860B1 (en) * | 1998-10-15 | 2001-10-09 | Fluoro Probe, Inc. | Method for viewing diseased tissue located within a body cavity |
US6652836B2 (en) | 1998-10-15 | 2003-11-25 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
CN1358171A (en) * | 1999-06-08 | 2002-07-10 | 拉卓拉药物公司 | Valency platform molecules comprising aminooxy groups |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
AU2001227679A1 (en) * | 2000-02-25 | 2001-09-03 | General Atomics | Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods |
US6844318B2 (en) * | 2000-03-15 | 2005-01-18 | Bristol Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
WO2001071352A2 (en) * | 2000-03-17 | 2001-09-27 | The Salk Institute For Biological Studies | Compositions associated with complex formation |
US6610504B1 (en) | 2000-04-10 | 2003-08-26 | General Atomics | Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase |
CN1434726A (en) | 2000-06-08 | 2003-08-06 | 拉卓拉药物公司 | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
EP1307216A4 (en) * | 2000-07-12 | 2005-01-12 | Gryphon Therapeutics Inc | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
AU7338501A (en) * | 2000-09-08 | 2002-03-22 | Gryphon Sciences | Polymer-modified synthetic proteins |
US7118737B2 (en) * | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
EP1333811A4 (en) * | 2000-10-16 | 2004-03-03 | Neopharm Inc | Liposomal formulation of mitoxantrone |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US7265186B2 (en) * | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
AU2003300380B2 (en) * | 2002-12-30 | 2008-11-06 | Nektar Therapeutics | Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles |
WO2004062588A2 (en) * | 2003-01-06 | 2004-07-29 | University Of Utah | Water-soluble polymeric bone-targeting drug delivery system |
US20050090804A1 (en) * | 2003-10-22 | 2005-04-28 | Trivascular, Inc. | Endoluminal prosthesis endoleak management |
FR2863619B1 (en) * | 2003-12-11 | 2007-04-20 | Oreal | COPOLYMER ROD-COIL AND COSMETIC APPLICATION |
US7354980B1 (en) | 2004-03-12 | 2008-04-08 | Key Medical Technologies, Inc. | High refractive index polymers for ophthalmic applications |
US7384760B2 (en) * | 2004-04-30 | 2008-06-10 | General Atomics | Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase |
WO2005115457A2 (en) * | 2004-05-10 | 2005-12-08 | University Of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
US7446157B2 (en) | 2004-12-07 | 2008-11-04 | Key Medical Technologies, Inc. | Nanohybrid polymers for ophthalmic applications |
US20100092505A1 (en) | 2005-04-05 | 2010-04-15 | Elisabetta Bianchi | Method for Shielding Functional Sites or Epitopes on Proteins |
ATE524509T1 (en) * | 2005-07-18 | 2011-09-15 | Nektar Therapeutics | BRANCHED FUNCTIONALIZED POLYMERS USING BRANCHED POLYOLS AS CORE |
CN100365043C (en) * | 2006-04-06 | 2008-01-30 | 北京理工大学 | Synthesis of ABA polypeptide -b- polytetrahydrofuran-b-polypeptide triblock copolymer |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
EP3486653A1 (en) | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
US8178617B2 (en) * | 2007-07-16 | 2012-05-15 | Allvivo Vascular, Inc. | Antimicrobial constructs |
EP2197340A4 (en) * | 2007-09-19 | 2015-10-21 | Oncofluor Inc | Method for imaging and treating organs and tissues |
JP5624027B2 (en) | 2008-05-27 | 2014-11-12 | ジェンザイム・コーポレーション | Peptide analogues of α-melanocyte stimulating hormone |
JP5580329B2 (en) | 2008-12-05 | 2014-08-27 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | SPARC binding peptides and uses thereof |
US9155801B2 (en) | 2009-05-28 | 2015-10-13 | The United States Government As Represented By The Department Of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
HUE029855T2 (en) | 2011-07-05 | 2017-04-28 | Bioasis Technologies Inc | P97-antibody conjugates |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
US9532866B2 (en) * | 2012-03-15 | 2017-01-03 | L&C Bio Co., Ltd. | Acellular dermal graft |
CA2880162C (en) | 2012-07-31 | 2023-04-04 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
AU2013341711A1 (en) | 2012-11-12 | 2015-05-21 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
WO2014078733A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
BR112015022416A2 (en) | 2013-03-13 | 2017-10-24 | Bioasis Technologies Inc | p97 fragments and their uses |
US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
CN105744935B (en) | 2013-11-27 | 2022-09-30 | 雷德伍德生物科技股份有限公司 | Hydrazino-pyrrolo compounds and methods for forming conjugates |
EP3215537B1 (en) | 2014-11-05 | 2022-01-05 | Nanyang Technological University | Stabilized and autonomous antibody vh domain |
US11590242B2 (en) | 2016-06-15 | 2023-02-28 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
US20190330317A1 (en) | 2016-06-15 | 2019-10-31 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
CN111094462A (en) | 2017-12-26 | 2020-05-01 | 贝克顿·迪金森公司 | Deep ultraviolet excitable water-solvated polymer dyes |
US20210054102A1 (en) | 2018-02-01 | 2021-02-25 | Yale University | Compositions and methods for enhancing nuclear translocation |
CN112384573A (en) | 2018-03-30 | 2021-02-19 | 贝克顿·迪金森公司 | Water-soluble polymeric dyes containing pending chromophores |
WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
EP4182475A2 (en) | 2020-07-17 | 2023-05-24 | Onena Medicines S.L. | Antibodies against lefty proteins |
WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
WO2023056450A1 (en) | 2021-09-30 | 2023-04-06 | Yale University | Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024064752A2 (en) | 2022-09-20 | 2024-03-28 | Yale University | Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD287949A5 (en) * | 1989-09-15 | 1991-03-14 | Adw Zi F. Molekularbiologie,De | PROCESS FOR THE PRODUCTION OF COMPOUNDS WITH BIOLOGICAL ACTIVITY |
WO1992000748A1 (en) * | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
WO1993002712A1 (en) * | 1991-08-01 | 1993-02-18 | Danbiosyst Uk Limited | Preparation of microparticles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1302066B (en) * | 1963-06-10 | 1969-11-13 | Avny Yair | Method for grafting polypeptide chains onto polyhydroxy polymers |
DE2433883C2 (en) * | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Use of physiologically active polypeptides |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
-
1994
- 1994-02-28 US US08/203,106 patent/US5618528A/en not_active Expired - Fee Related
-
1995
- 1995-02-28 MX MX9603680A patent/MX9603680A/en unknown
- 1995-02-28 WO PCT/GB1995/000418 patent/WO1995022991A2/en not_active Application Discontinuation
- 1995-02-28 CA CA002183766A patent/CA2183766A1/en not_active Abandoned
- 1995-02-28 JP JP7522220A patent/JPH09509443A/en active Pending
- 1995-02-28 EP EP95909864A patent/EP0748226A1/en not_active Withdrawn
- 1995-02-28 CN CN95192754A patent/CN1146726A/en active Pending
- 1995-02-28 AU AU18170/95A patent/AU1817095A/en not_active Abandoned
-
1997
- 1997-02-03 US US08/790,854 patent/US5853713A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD287949A5 (en) * | 1989-09-15 | 1991-03-14 | Adw Zi F. Molekularbiologie,De | PROCESS FOR THE PRODUCTION OF COMPOUNDS WITH BIOLOGICAL ACTIVITY |
WO1992000748A1 (en) * | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
WO1993002712A1 (en) * | 1991-08-01 | 1993-02-18 | Danbiosyst Uk Limited | Preparation of microparticles |
Non-Patent Citations (9)
Also Published As
Publication number | Publication date |
---|---|
JPH09509443A (en) | 1997-09-22 |
AU1817095A (en) | 1995-09-11 |
EP0748226A1 (en) | 1996-12-18 |
CN1146726A (en) | 1997-04-02 |
WO1995022991A2 (en) | 1995-08-31 |
US5853713A (en) | 1998-12-29 |
MX9603680A (en) | 1997-06-28 |
CA2183766A1 (en) | 1995-08-31 |
US5618528A (en) | 1997-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995022991A3 (en) | Block copolymers | |
AU2272097A (en) | Drug delivery compositions suitable for intravenous injection | |
CA2277824A1 (en) | Dosage composition for nasal delivery and method of use of the same | |
SI0817621T1 (en) | Pharmaceutical composition for transdermic delivery | |
AU7796198A (en) | Novel acoustically active drug delivery systems | |
AU5945296A (en) | Medicament for nasal administration | |
AU6075198A (en) | Drug delivery system for two or more active substances | |
HUP0001914A3 (en) | Biocompatible compounds for pharmaceutical drug delivery systems | |
EP0662851A4 (en) | Drug delivery system. | |
CA2329005A1 (en) | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems | |
CZ20011581A3 (en) | System for administering biologically active compound by inhalation | |
ZA962248B (en) | Nanususpensions for intravenous administration | |
ES2130423T3 (en) | INTRAVAGINAL ADMINISTRATION SYSTEM. | |
AU7369287A (en) | Sustained release formulations | |
MX9602683A (en) | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances. | |
IL136285A0 (en) | Pharmaceutical compositions containing an acid-labile active component | |
AU4505496A (en) | Sustained-release drug delivery system | |
EP0828481A4 (en) | Oral dosage composition for intestinal delivery and method of use of the same | |
EP1310244A3 (en) | Compositions comprising an anticancer agent and a polyether block copolymer | |
AU2999995A (en) | Self-emulsifying drug delivery system | |
AU6175398A (en) | New delivery system for administering dentin-hypersensitivity-ameliorating compositions | |
MX9709453A (en) | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form. | |
NZ501832A (en) | Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system | |
CA2129676A1 (en) | Dextromethorphan Antitussive Compositions | |
ATE234096T1 (en) | PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION CONTAINING THE ACTIVE INGREDIENT MORPHINE-6-GLUCURONIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95192754.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2183766 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995909864 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995909864 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995909864 Country of ref document: EP |